Veracyte, Inc. (VCYT)

From the record

Veracyte, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Veracyte, Inc.'s 10 filed years say what it did: revenue went from $65 million in fiscal 2016 to $517 million in fiscal 2025, up 25.9% a year; it rose in 8 of 9 years; the deepest fall was 2% from fiscal 2019 to fiscal 2020; net income was positive in 2 of 8 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Veracyte, Inc.'s diluted share count grew about 4.0% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 61 sales (58 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-29 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Veracyte, Inc. earned about 5 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 26 cents per dollar of everything the company owns. Leverage: it owed about 7 cents per dollar of assets, and net share issuance: its share count grew 3.1% over the year (the filed statements).

From the record

Veracyte, Inc.'s standing among 24 graded names in its industry family: revenue of $517 million in fiscal 2025 ranks in the top 28% by size; a net margin of 12.8% ranks in the top 10%; revenue growth of 20.4% a year over the last 3 filed years ranks in the top 41% (its annual reports).

From the record

Veracyte, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Stapley, Marc (Chief Executive Officer, as filed), filing under that title since 2021-06-03, 5.4 years (top 38% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 4.7 years (bottom 23%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Veracyte, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $363 million against no long-term debt tagged leaves 25.8% of its assets as net cash, top 33% of its family; cash from operations less capital spending is 24.5% of revenue (top 6%); a gross margin of 70.1% (top 16%); research spending of 13.7% of revenue (bottom 31%) (its annual report).

From the record

Veracyte, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 20.4% a year over the last three filed years against 25.9% over all 10, slowing (bottom 41% of its family); the newest year grew 16% (top 46%); research spending grew 20.4% a year (top 31%); capital spending grew 4.2% a year (top 45%) (its annual reports). Veracyte, Inc. reported 5 product lines in fiscal 2025: Testing at $493 million (95%), Biopharmaceutical and Other at $10 million (2%), Biopharmaceutical and Other Biopharmaceutical Revenue at $7 million (1%), and 2 more; 1 of 5 grew against the year before (its annual report).

From the record

Veracyte, Inc.'s newest year against its own record: revenue of $517 million in fiscal 2025 came in 5.4% below the $546 million its prior three years' pace pointed to (bottom 48% of its family); net income of $66 million against a prior three-year average of $29 million (top 2%); a net margin of 12.8% against -9.2% before (bottom 48%) (its annual reports).